Pomerantz LLP is investigating claims on behalf of investors of aTyr Pharma, Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR).Such investors are advised to contact Danielle Peyton at newaction@pomlaw.comor 646-581-9980, ext.7980.
https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg
The investigation concerns whether aTyr and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On September 15, 2025, aTyr issued a press release “announce[ing] topline results from the Phase 3 EFZO-FIT™ study of efzofitimod in 268 patients with pulmonary sarcoidosis, a major form of interstitial lung disease.” The press release disclosed, in relevant part, that the trial had failed to meet its primary endpoint.
On this news, aTyr's stock price fell sharply during intraday trading on September 15, 2025.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980
https://edge.prnewswire.com/c/img/favicon.png?sn=DC75070&sd=2025-09-18
View original content to download multimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-atyr-pharma-inc—atyr-302558804.html
SOURCE Pomerantz LLP
https://rt.newswire.ca/rt.gif?NewsItemId=DC75070&Transmission_Id=202509181000PR_NEWS_USPR_____DC75070&DateId=20250918